TCRX vs. REPL, TRML, OCGN, ALVO, SLDB, FATE, LXEO, ITOS, BDTX, and ADPT
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Replimune Group (REPL), Tourmaline Bio (TRML), Ocugen (OCGN), Alvotech (ALVO), Solid Biosciences (SLDB), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), iTeos Therapeutics (ITOS), Black Diamond Therapeutics (BDTX), and Adaptive Biotechnologies (ADPT). These companies are all part of the "biological products, except diagnostic" industry.
TScan Therapeutics (NASDAQ:TCRX) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.
In the previous week, TScan Therapeutics had 5 more articles in the media than Replimune Group. MarketBeat recorded 6 mentions for TScan Therapeutics and 1 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.93 indicating that Replimune Group is being referred to more favorably in the news media.
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 20.6% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Replimune Group has a net margin of 0.00% compared to TScan Therapeutics' net margin of -423.86%. Replimune Group's return on equity of -42.94% beat TScan Therapeutics' return on equity.
TScan Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
TScan Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 54.04%. Replimune Group has a consensus target price of $37.67, indicating a potential upside of 461.35%. Given Replimune Group's higher probable upside, analysts clearly believe Replimune Group is more favorable than TScan Therapeutics.
Replimune Group received 132 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 71.43% of users gave TScan Therapeutics an outperform vote while only 61.54% of users gave Replimune Group an outperform vote.
TScan Therapeutics has higher revenue and earnings than Replimune Group. TScan Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
Summary
Replimune Group beats TScan Therapeutics on 9 of the 16 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
